Aarhus University Seal

About FMT

What is FMT?

Faecal microbiota transplantation (FMT) is a medical treatment, 
where intestinal microbiota is transplanted to the intestines of a patient, 
using faeces from a healthy donor.


FMT in Denmark

FMT is considered for patients with recurrent C difficile infection in all Danish hospitals.

The use of FMT in Denmark is described in a National Danish clinical guideline, published in 2021 following joint consensus between four scientific societies:

FMT in Europe

FMT is used in routine clinical care and in experimental studies throughout Europe.

At present, the use of FMT in Europe is unevenly distributed, demonstrated in a Europe-wide survey conducted in 2020.

All academic institutions in Europe are invited to join the EurFMT network that currently counts more than 35 centres from 19 European countries. Access the EurFMT including newsletters and links here.

European Microbiota newsletter: Within the European FMT Network, we issue four European FMT newsletters each year. Access the newsletters and subscribe for future newsletters here.
 

FMT Methods

FMT framework, CEFTA – Jørgensen 2017

FMT capsule protocol, CEFTA  – Hansen 2024

Tissues and cells

The Council of Europe issues the technical guide for the safety and quality of tissues and cells for human application. 

The revised 6th edition of the tissue and cells guide was published in October 2026 and can be downloaded at the EDQM website. The chapter on intestinal microbiota has been thoroughly revised and includes guidance to regulatory standards, good practice guidance, recommendations, and supplementary information as well as monographs on liquid suspensions and encapsulated donor faeces.

EU regulation: SoHO

Substance of human origin (SoHO) is a term applied by the European Commission to embrace blood, tissues, cells, organs and human-derived material such as breast milk and intestinal microbiota.

Following five years of preparation, the new SoHO Regulation was published in 2024 and is implemented from 2027. 
Read about the process here and see the SoHO regulation here.

The SoHO Coordination Board (SCB) provides an overview of the preparation for the full implementation as well as key documents. Follow the SoHO Coordination Board here.

Microbiota modulation

Intestinal microbiota is a key determinant of human health. The synergy between host and microbiome affects diseases in all tissues of the human organism. Development of diseases such as Crohn’s disease, multiple sclerosis, diabetes mellitus, and obesity is linked to disturbances in the intestinal microbiome, termed dysbiosis. It is not clear if dysbiosis causes disease or rather develops as a consequence of disease.

Since two multicenter studies in Europe and USA (MetaHIT and Human Microbiome Project) provided in-depth analyses of the human intestinal microbiota, using next-generation sequencing methods, our understanding of “our other genome” has increased massively. We now know multiple ways to modulate the intestinal microbiome, using either diet, medications such as antibiotics, cultured microorganisms (probiotics), or faecal microbiota transplantation.

Our microbiomes are under constant development, and attempts to conserve microbiota for the future include the microbiota vault.

Links

Clinical trials

Use of medical treatments is best investigated by clinical trials. ClinicalTrials.gov is a public registry of ongoing clinical trials, currently including more than 100 trials investigating the use of FMT in humans.

Results from clinical trials are published in scientific journals following peer review. Findings from different trials may be combined and analysed in systematic reviews and meta-analyses. Find CEFTA publications of clinical trials, systematic reviews, and meta-analyses under “Publications”.

  • FMT for C difficile infection
    A meta-analysis documented the effect of FMT for recurrent C difficile infection – 81% following one FMT and 91% following repeat FMT. The number needed to treat, i.e. the number of patients needed to treat in order to achieve week 8 resolution of disease, is 1.5.
    (Open access via EClinicalMedicine)
     
  • Early FMT in patients with C difficile infection
    In a double-blinded, placebo-controlled clinical trial, we planned to randomise 84 patients with their first or second episode of C. difficile to receiving either encapsulated FMT or encapsulated placebo following standard therapy with oral vancomycin. The primary outcome was resolution of C difficile-associated disease 8 weeks after treatment. The study was stopped after an interim analysis of the first 42 randomised patients due to a marked effect difference between patients who had received active FMT and those who had received placebo. The study was published in September 2022 in Lancet Gastroenterology and Hepatology.
     
  • Comprehensive geriatric assessment of older patients with C. difficile
    Older patients with C. difficile are frail and comorbid, and mortality rates are high. Their frailty burden may restrict access to treatments such as CDI-specific antibiotics and faecal microbiota transplantation (FMT). We investigated clinical effects of early comprehensive geriatric assessment (CGA) and frailty evaluation, including home visits and assessment for FMT, in older patients with CDI. In a randomised quality improvement trial (NCT05447533) with a pragmatic design, patients aged 70+ years with a positive PCR test for Clostridioides difficile were assigned (1:1) to CGA or standard care (S), both with equal access to FMT. Patients and investigators were unmasked. The primary outcome was 90-day mortality. Secondary outcomes included CDI recurrence, days in hospital, 30-day readmission and time to treatment with FMT.
    We included 217 patients and randomised them to a geriatric assessment or standard care. We found a numerically lower 90-days mortality from in the group that received the geriatric assessment (16% versus 20%), but the difference was not statistically significant. Importantly, acute readmissions were 67% lower in the assessment group, and deaths attributable to C. Difficile were fewer. Most improvements could re related to early use of FMT. Read the full paper here and the health economic assessment here. 
     
  • FMT for diabetes mellitus type 1 with chronic diarrhea
    Chronic diarrhea in patients with diabetes mellitus type 1 may result from a colonic dysbiosis. In this double-blinded, placebo-controlled clinical trial, we randomise patients with diabetes mellitus type 1 and chronic diarrhea to either FMT week 0 and FMT week 4 or placebo week 0 and FMT week 4, with safety as the main outcome and symptom scores week 8 as secondary outcome measures.
    In the study, we included 20 patients and randomised them to FMT or placebo. The findings indicated a positive effect of FMT om both symptoms and quality of life, and the treatment was well tolerated. A larger clinical trial is ongoing. Read the initial report here and results from long-term open label therapy here. 
     
  • FMT for irritable bowel syndrome
    Several clinical studies have been conducted, yielding different results, ranging from a marked difference between FMT and placebo in favour of placebo, via studies finding no difference, to studies finding a discrete, but statistically significant difference in favour of FMT. This Danish study found placebo treatment superior to FMT. (Open access via Gut, a BMJ journal)
    A recently published multicenter study from Norway included 450 patients. Of these, 300 were randomised to FMT and 150 to placebo. The researchers found no difference between FMT and placebo to reduce the symptoms in IBS. Read the study here. 
     
  • FMT for decompensated liver cirrhosis 
    Liver cirrhosis is associated with marked dysbiosis, i.a. an altered microbiota composition. Pilot trials indicate that patients with hepatic encephalopathy, a life-threatening complication of liver cirrhosis, may benefit from FMT.